User login
The Food and Drug Administration has approved several generic formulations of the atypical antipsychotic aripiprazole, the agency announced April 28.
Aripiprazole was approved in 2002 for the treatment of schizophrenia and is marketed as Abilify by the Otsuka Pharmaceutical. It is now also approved for indications that include bipolar disorder. Multiple dosage forms and strengths of generic aripiprazole have been approved, according to the FDA statement.
The generic manufacturers are Alembic Pharmaceuticals, Hetero Drugs, Teva Pharmaceuticals, and Torrent Pharmaceuticals.
The Food and Drug Administration has approved several generic formulations of the atypical antipsychotic aripiprazole, the agency announced April 28.
Aripiprazole was approved in 2002 for the treatment of schizophrenia and is marketed as Abilify by the Otsuka Pharmaceutical. It is now also approved for indications that include bipolar disorder. Multiple dosage forms and strengths of generic aripiprazole have been approved, according to the FDA statement.
The generic manufacturers are Alembic Pharmaceuticals, Hetero Drugs, Teva Pharmaceuticals, and Torrent Pharmaceuticals.
The Food and Drug Administration has approved several generic formulations of the atypical antipsychotic aripiprazole, the agency announced April 28.
Aripiprazole was approved in 2002 for the treatment of schizophrenia and is marketed as Abilify by the Otsuka Pharmaceutical. It is now also approved for indications that include bipolar disorder. Multiple dosage forms and strengths of generic aripiprazole have been approved, according to the FDA statement.
The generic manufacturers are Alembic Pharmaceuticals, Hetero Drugs, Teva Pharmaceuticals, and Torrent Pharmaceuticals.
